Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 25Other solid neoplasm 10Thoracic 8Lymphoid 5Head & Neck 4Genitourinary 4Breast 4Tumor-Agnostic 2Other hematologic neoplasm 2Sarcoma 1NET 1Gynecologic 1Endocrine 1Dermatologic 1

Conditions

Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 3surufatinib 2pembrolizumab 2olaparib 2lanreotide 2atezolizumab 2Everolimus 23-Iodobenzylguanidine 2tivozanib 1tislelizumab 1repotrectinib 1regorafenib 1pralsetinib 1irinotecan sucrosofate 1cabozantinib 1avelumab 1arginyllysine 1amino-acid, glucose, and electrolyte solution 1Tirapazamine 1Temozolomide 1TKM-080301 1S 1 (combination) 1Radiotherapy 1Positron-Emission Tomography 1Positron Emission Tomography Computed Tomography 1PT-100 dipeptide 1PM 01183 1Ondansetron 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × tislelizumab × NET × Clear all
NCT04579757 2025-05-08

Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors

Hutchmed

Phase 1/2 Terminated
87 enrolled 29 charts
EndocrineGastrointestinalHead & NeckNETSarcomaThoracic

Neoplasm Metastasis, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Neuroendocrine Tumors, Small Cell Lung Carcinoma, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡